Relative burdens of the COVID-19, malaria, tuberculosis and HIV/AIDS epidemics in sub-Saharan Africa.

David Bell[1*], Kristian Schultz Hansen[2]

[1]Independent Consultant, Issaquah, Washington, USA

[2]Department of Public Health and Centre for Health Economics and Policy, University of Copenhagen, Øster Farimagsgade 5A, 1014 Copenhagen K, Denmark.

*Corresponding author

David Bell, , Issaquah, WA 98027, USA, Email: bell00david@gmail.com, Ph: +1 206 953 8354

Transparency statement

The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that there are no discrepancies from the study as originally planned.

Word count: Abstract 246, Main text: 2080

List of abbreviations

Africa CDC	Africa Centres for Disease Control and Prevention
AIDS	Acquired Immune Deficiency Syndrome
DALYs	Disability-Adjusted Life Years
HIV	Human Immunodeficiency Virus
SARS-CoV-2	Severe Acute Respiratory Syndrome Corona Virus -2
WHO	World Health Organization

ABSTRACT

Objectives: COVID-19 has had considerable global impact, but in sub-Saharan Africa is one of several infectious disease priorities. Prioritization is normally guided by disease burden, but the highly age-dependent nature of COVID-19 and other infectious diseases makes comparisons challenging unless considered through metrics that incorporate life years lost and time lived in adverse health. We compared the burdens of COVID-19 and three major epidemic-causing pathogens; malaria, tuberculosis and HIV/AIDS.

Design: We compared estimates of 12-month disease burdens in sub-Saharan African populations through mortality and Disability-Adjusted Life Years lost (DALYs) for COVID-19, malaria, tuberculosis and HIV/AIDS, applying known age-related mortality to UN estimates of age structure. We further compared exacerbations disease burden predicted from the COVID-19 public health response. Data was derived from public sources, predicted exacerbations from those published by international agencies.

Main outcome measures: Mortality and DALYs lost

Results: For sub-Saharan African populations north of South Africa, recorded COVID-19 DALYs lost in 2020 was 3.7%, 2.3% and 2.4% of those estimated for tuberculosis, HIV/AIDS and malaria respectively. The predicted exacerbations alone of these comparator diseases were greater than the estimated COVID-19 burden. Including South Africa and Lesotho, COVID-19 DALYs lost were <12% of those for comparator diseases and dominated by them in all age groups below 65 years.

Conclusions: The analysis suggests a relatively low impact from COVID-19. While all four epidemics continue, concentration on COVID-19 runs a high risk of increasing the overall health burden, further increasing global inequities in health and life expectancy.

MAIN MANUSCRIPT

Introduction

COVID-19 has massively impacted life and society in sub-Saharan Africa, as elsewhere. Despite relatively low COVID-19 mortality rates in most countries of sub-Saharan Africa, aspects of the lockdown responses including business and school closures and restricted health service access introduced in the early days of the pandemic continue in various forms.[1] In South Africa, infection with the virus itself has significantly impacted health, with 28469 deaths attributed by the end of 2020,[1] but the younger aged populations to the north have recorded far lower mortality.[2] Public health interventions must be tailored to address such variation. This requires realistic metrics for disease burden that take the characteristics of the population, and the individual impacted by disease, into account.[3]

Metrics encompassing life years lost or disrupted are critical when comparing diseases that are strongly age-associated. A young child dying from pneumonia is clearly expected to lose more potential life years than an 80-year-old dying from the same. Malaria, with its mortality centred in these countries, imparts a disproportionate burden in disability adjusted life years (DALYs) lost, as most mortality occurs before age five.[4] HIV/AIDS leads to long spells of severe ill-health and premature death primarily among young and middle-aged adults leading to significant life years lost and extended time lost due to less-than-optimal health. In contrast, COVID-19 is characterized by it's strong association with advanced age, with a mean age of death similar to that for all-cause mortality in many countries.[5,6] However, reporting of the burden of COVID-19 has generally it centred on comparisons of mortality which ignore the influence of age. These mortality-based burden estimates can further mislead through the strong association of death from COVID-19 with pre-existing morbidities, which further reduce expected life years lost from most COVID-19-associated deaths.[6] Time-based measures such as Disability-Adjusted Life Years (DALYs) that incorporate lost healthy life caused both by premature death and time lived in less-than-optimal health have potential to better represent the full disease impact – as opposed to mortality alone.

Low COVID-19-associated mortality among sub-Saharan African populations is at least partially predicted by their young age structure,[5,7] while lifestyle factors may be protective through a lower prevalence of major co-morbidities,[8-10] higher vitamin D levels and broad antigen exposure leading to non-specific T-cell prior immunity.[11-13] Comparisons of lockdown severity suggest that more restrictive measures have had limited additional impact on reducing COVID-19 mortality.[14-16] However, as with many public health responses,

lockdown responses are not without cost. Predicted exacerbations of high burden diseases including malaria, HIV/AIDS and tuberculosis impact particularly children and younger adults.[17-19] Broader impacts of reduced food security and interruption of vaccination will have far-reaching health consequences,[20,21] while loss of family income and reductions in national gross domestic product will impede the capacity to respond.[22]

While lockdowns may be easing, proposals for continent-wide mass vaccination under the COVAX mechanism will raise new costs and divert resources, and the urgency of developing good public health policy that appropriately prioritizes relative burdens including COVID-19 management are no less urgent.[23] We therefore compared the disease burdens of COVID-19 and the three pre-existing major infectious disease 'epidemics' of sub-Saharan African countries,[24] with and without South Africa and Lesotho, to estimate the relative burden of COVID-19 in relation to these other epidemics.

Methods

The health indicators used for the analyses were the number of deaths and Disability-Adjusted Life Years (DALYs) lost by age groups caused by COVID-19 and three major diseases: malaria, HIV/AIDS and tuberculosis. Published data were the main sources of the presented analyses. For the calculation of DALYs lost caused by these diseases at population level, the estimates for number of deaths by age and the number of non-fatal episodes of ill-health by age in 2020 were required. Estimates with and without South Africa and Lesotho were included as these two countries have very different burdens of the four diseases, and differing demographics.

As COVID-19 cases were reported from Africa in February 2020 and widely spread by late March, all recorded COVID-19 deaths were included up until 31 March 2021 to include slightly over 12 months of reporting. According to Africa CDC there had been 77,463 reported COVID-19 deaths in sub-Saharan Africa up to March 2021 and 24,302 COVID-19 deaths if South Africa and Lesotho were excluded.[2] These total number of reported COVID-19 deaths were allocated across age groups and also used to estimate the number of COVID-19 infections by applying the following method and assumptions. Using data on COVID-19 deaths and seroprevalence surveys from 45 mainly European countries, O'Driscoll et al estimated the infection fatality ratio by age.[25] Assuming that these estimated infection fatality ratios also represented the sub-Saharan African situation and further assuming a constant share of infection across age groups, the number of infections and

deaths were inferred for a sub-Saharan Africa population size according to United Nations population estimate for 2020 and compatible with a total number of 77,463 (24,302) COVID-19 deaths (see Table S1 in the supplementary material).[26] These estimated numbers of deaths and infections by age group were inserted in the standard DALY formula used for calculating the burden of disease and with no discounting of future life years and without the age weighting function.[27] For the calculation of life years lost, the standard life expectancies by age from the Global Burden of Disease Study 2019 were used,[28] and the reference life table was downloaded from the Institute of Health Metrics and Evaluation website.[29] The non-fatal COVID-19 infections were assumed to be mild of a two-week duration and using a disability weight of 0.051 corresponding to the weight attached to a moderate to severe upper respiratory infection.[28]

The number of deaths and DALYs lost for HIV/AIDS and tuberculosis by age group for 2019 were extracted from the Global Burden of Disease Study 2019 results.[29] These estimates were updated to 2020 by assuming a growth from 2019 to 2020 corresponding to the annual population growth rate in sub-Saharan Africa. Population growth rates were estimated by age group using population estimates from 2015 and 2020.[26] Cases of combined HIV/AIDS and tuberculosis are considered as HIV/AIDS only and not included in the tuberculosis burden calculations.

Total number of deaths and non-fatal illness episodes caused by malaria in sub-Saharan Africa were obtained from the WHO estimates for 2019,[4] however, the published numbers were not available by age group. It was assumed that the deaths and illness spells followed the same distribution across age groups as malaria deaths as estimated by the Institute of Health Metrics and Evaluation.[29] The number of malaria deaths and illness episodes by age in sub-Saharan Africa (with and without South Africa and Lesotho) were translated into DALYs lost applying the same method as described above including the assumption that a non-fatal malaria infection lasted two weeks and with a disability weight of 0.051.

Predicted exacerbations of the three comparator diseases accrued from 2020 lockdown responses were derived from modelling published by the World Health Organization, StopTB Partnership and The Global Fund.[17-19]

Results

Recorded COVID-19 mortality constituted 6.4%, 4.8% and 6.3% of the mortality of tuberculosis, HIV/AIDS and malaria respectively in sub-Saharan Africa north of South Africa and Lesotho. As DALYs lost, the COVID-19 burden amounted to 3.7%, 2.3% and 2.4% of that estimated for the three comparator diseases respectively (Figure 1). Tuberculosis mortality was never dominated by COVID-19 in any age-group, while HIV/AIDS is only dominated above 75 years of age and malaria equaled at 80 years (Figure 2).

Including South Africa and Lesotho, COVID-19 mortality and DALYs lost were 19.2%, 11.7% and 20.2%, and 11.1%, 5.5% and 7.5% of tuberculosis, HIV/AIDS and malaria respectively (Figure 1). All three comparator diseases individually dominated COVID-19 mortality until 65-69 years where COVID-19 dominated HIV/AIDS, and 70-74 years where malaria was also dominated (Figure 2).

Accrued COVID-19 DALYs lost up to 31 March 2021 were also lower than the lower-limit estimates of exacerbation of malaria, tuberculosis and HIV/AIDS (increase over baseline) predicted due to the COVID-19 public health response in sub-Saharan Africa north of South Africa, well below those for tuberculosis and HIV/AIDS for sub-Saharan Africa as a whole. If we assume significant under-reporting of COVID-19, arbitrarily multiplying by a factor of 10 only dominates the lower predicted exacerbations of malaria-burden, and remains below all disease burdens of tuberculosis and HIV/AIDs in sub-Saharan Africa as a whole, and all comparator diseases where South Africa and Lesotho are excluded (Table 1).

Table 1. Comparisons of recorded disease burden (DALYs lost) from COVID-19 in sub-Saharan Africa up till 31 March 2021 compared to predicted exacerbations for malaria, tuberculosis and HIV/AIDS from the impact of the COVID-219 public health response.

		DALYs lost			
		COVID-19	**Malaria**	**Tuberculosis**	**HIV/AIDS**
Sub-Saharan Africa (SSA)	**Baseline**	2,004,768	26,798,253	18,057,844	36,674,765
	Exacerbation - low	-	1,901,866	10,769,549	15,579,790
	Exacerbation - high	20,047,677	26,783,055	14,095,787	24,474,183
SSA excluding South Africa and Lesotho	**Baseline**	636,295	26,797,264	17,051,568	28,253,799
	Exacerbation - low	-	1,907,695	10,169,414	12,002,484
	Exacerbation - high	6,362,955	26,793,081	13,310,297	18,854,617



Figure 1. Comparison of baseline mortality and disease burdens (DALYs lost) predicted for the 12 months of 2020 for malaria, tuberculosis and HIV/AIDs (pre-lockdown impact), and up to 31 March 2021 for COVID-19, in sub-Saharan Africa. A1 & A2: Mortality and DALYs lost for sub-Saharan countries north of South Africa and Lesotho. B1 & B2: Mortality and DALYs lost for all sub-Saharan countries.



Figure 2. Mortality predicted for the 12 months of 2020 for malaria, tuberculosis and HIV/AIDs (pre-lockdown impact), and up to 31 March 2021 for COVID-19, in sub-Saharan Africa. A: Mortality for sub-Saharan countries north of South Africa and Lesotho. B: Mortality for all sub-Saharan countries.

Discussion

These comparisons emphasize the relatively low disease burden that COVID-19 is exerting on sub-Saharan African populations, with the pre-existing 'epidemics' of malaria, tuberculosis and HIV/AIDS all greatly dominating in life-years impacted, with mortality dominating also in all except the elderly. The use of DALYs lost to assess relative disease burden follows well-accepted practice,[30,31] but is relatively unusual for assessment of COVID-19. It is unclear why this standard public health metric, or the related metric of Quality-Adjusted Life Years (QALYs), has not been widely applied to a disease with such a characteristic age-dependent impact. Appropriate assessment of burden is of extreme importance as decisions are made globally on resources to be allocated to vaccination as well as the imposition of recurrent lockdowns and other cost-bearing responses. Mass vaccination of the sub-Saharan African population against COVID-19, as is advocated in some

quarters,[23] will draw essential resources from interventions aimed at health problems with far greater burden through diversion of financial resources and personnel on the ground. Such a wide-scale vaccine intervention has never been attempted before and the implications for already over-stretched health services will be significant. To ensure equity in health care, comprehensive economic evaluation comparing costs and effects of interventions against all four epidemics, including cost-effectiveness analysis, is urgently needed.

This data analysis has a number of limitations. COVID-19 mortality reporting in sub-Saharan Africa is doubtless incomplete, though low mortality is predicted by population age structure and lower prevalence of major co-morbidities including obesity,[5,7,32] while other lifestyle factors and prior immunity may also be protective.[10,33-35] Given lack of strong local data on age-related mortality, we assumed that mortality rates reflect those found elsewhere.[25] Lack of transmission appears an unlikely explanation for low recorded mortality as high seroprevalence has been recorded in various sub-Saharan African settings.[36-40] While the higher mortality of COVID-19 in South Africa could be partially explained by higher reporting rates, South Africa also has higher rates of known mortality risk factors.[41] Evidence of very high asymptomatic infection,[40] and the level of testing taking place (868823 tests for 333 deaths in Uganda alone by 23 February 2021),[42] suggests that the low recorded mortality in most countries reflects reality, in common with much of Asia.[43]

The relative burden of COVID-19 in 2020 is also subject to the first cases only being reported in March in most of these populations,[43] and so it will not have been in all populations within the first few months of recording. However, as the total mortality rate is declining across the continent at time of writing,[43] the bulk of COVID-19 burden may well been accrued in the >12 months total recording time used here.

DALYs lost through COVID-19 morbidity as estimated in this paper do not take post-viral syndromes into account (e.g. ‘long-covid’). These have limited prevalence and may be lighter in younger (less severe illness) African populations, but this is still unclear and will add somewhat to COVID-19 burden. Conversely, the age-based nature of DALYs lost applied to COVID-19 does not take into account the high prevalence of life-shortening comorbidities associated with these cases,[6] which will in turn lead to an over-estimation of the actual life years lost. Even assuming 90% under-estimation of COVID-19 mortality here, other single disease metrics still dominate COVID-19, as do most estimates of exacerbation of these through the COVID-19 public health response.

In comparing impact of COVID-19 and other health burdens, we considered just three diseases. The impact of broad malnutrition, and of reduced educational attainment (closed schools) and damage to local and national economies will have major long-term impacts on population and societal health.[20-22,44] As a greater proportion of the population achieves post-infection immunity,[36-38,42,45,46] COVID-19 burden is likely to further reduce, and the cost-effectiveness of response interventions may then decrease further. It is therefore imperative that the cost-effectiveness analyses of further COVID-19 related interventions in these sub-Saharan African populations be tailored to local need, based on realistic metrics that reflect the relative impact of COVID-19, of other disease states, and of the proposed public health responses. Continued emphasis on COVID-19 responses including severe lockdowns or mass vaccination risk exacerbating other health priorities, increasing health inequities rather than reducing them.

Declaration of competing interests

No conflict of interest to declare.

Funding source:

None

Availability of data

All data is in the public domain, and calculations are freely available from the authors.

Dissemination statement

Dissemination to patients is not applicable.

Author contributions:

DB and KSH jointly conceived the study, contributed to the study design and conceptualization, and sourced the data. KSH performed the economic analyses, both authors participated in the drafting, revising and approval of the manuscript.

Declaration

The lead author (DB) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Patient and public involvement

There was no direct patient or public involvement in this study. All data used was in the public domain.

References

1. University of Oxford. Coronavirus government response tracker. Blavatnik School of Government. University of Oxford. 2021. (https://www.bsg.ox.ac.uk/research/research-projects/coronavirus-government-response-tracker),. Accessed 02 March 2021

2. Africa CDC. Coronavirus Disease 2019 (COVID-19): Latest updates on the COVID-19 crisis from Africa CDC. Africa Centres for Disease Control and Prevention, 2021. (https://africacdc.org/covid-19/). Accessed 01 January 2021.

3. WHO. WHO methods and data sources for global burden of disease estimates 2000-2015, Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2018.4. World Health Organization. 2018. (https://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf). Accessed. April 26, 2020.

4. WHO. World Malaria Report 2019. May 02, 2020. World Health Organization. Geneva. 2019. (https://www.who.int/publications-detail/world-malaria-report-2019). Accessed 11 March 2021.

5. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis.* 2020. Mar 30;S1473-3099(20)30243-7

6. CDC. COVID-19 Weekly Updates by Select Demographic and Geographic Characteristics. United States Centers for Disease Control and Prevention, (https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#AgeAndSex). Accessed 23 February 2021

7. UN. World population prospects. United Nations Department of Economics and Population Affairs – Population Dynamics. United Nations. New York, NY. 2019. May 02, 2020. (https://population.un.org/wpp/Download/Standard/Population/). Accessed 17 February 2021.

8. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.

9. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients.* 2020 Apr 2;12(4):988. doi: 10.3390/nu12040988. PMID: 32252338; PMCID: PMC7231123.

10. Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 2020 Nov 19;10(1):20191. doi: 10.1038/s41598-020-77093-z. PMID: 33214648; PMCID: PMC7677378.

11. Tan CCS, Owen CJ, Tham CYL, Bertoletti A, van Dorp L, Balloux F. 2020. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. *bioRxiv* 2020.12.08.415703; doi: https://doi.org/10.1101/2020.12.08.415703

12. Echeverría G, Guevara Á, Coloma J, Ruiz AM, Vasquez MM, Tejera E, de Waard JH. Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay. *Int J Infect Dis*. 2021; S1201-9712(21)00120-X. doi: 10.1016/j.ijid.2021.02.034.

13. CDC. Weekly Updates by Select Demographic and Geographic Characteristics - Comorbidities and other conditions. US Centers for Disease Control and Prevention. (https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?fbclid=IwAR3-wrg3tTKK5-9tOHPGAHWFVO3DfslkJ0KsDEPQpWmPbKtp6EsoVV2Qs1Q). Accessed 18 February 2021

14. De Larochelambert Q, Marc A, Antero J, Le Bourg E, Toussaint JF. COVID-19 Mortality: A Matter of Vulnerability Among Nations Facing Limited Margins of Adaptation. *Front Public Health*. 2020. 8:604339. doi: 10.3389/fpubh.2020.604339. PMID: 33330343; PMCID: PMC7710830.

15. Keep KP, Bjørnskov C. Lockdown 2020. Effects on Sars-CoV-2 Transmission – The evidence from Northern Jutland. m*edRxiv* 2020.12.28.20248936;
doi: https://doi.org/10.1101/2020.12.28.20248936

16. Chaudhry R, Dranitsaris G, Mubashir T, Bartoszko J, Riazi S. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on

COVID-19 mortality and related health outcomes. *EClinicalMedicine*. 2020. 25:100464. doi: 10.1016/j.eclinm.2020.100464.

17. WHO. The potential impact of health service disruptions on the burden of malaria: a modelling analysis for countries in sub-Saharan Africa. Geneva, Switzerland. World Health Organization. Geneva. 2020.

18. Stop TB Partnership. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: A modelling analysis. The Stop TB Partnership. 2020 (http://www.stoptb.org/assets/documents/news/Modeling%20Report_1%20May%202020_FINAL.pdf). Accessed 19 February 2021.

19. The Global Fund. 2020. Mitigating the impact if COVID-19 on countries affected by HIV, tuberculosis and malaria. The Global Fund to fight AIDS, Tuberculosis and Malaria. Geneva. (https://www.theglobalfund.org/media/9819/covid19_mitigatingimpact_report_en.pdf) . Accessed 19 February 2021.

20. World Food Programme. WFP Chief warns of hunger pandemic as COVID-19 spreads (Statement to UN Security Council). Originally published 21 Apr 2020. Relief Web. OCHA Services. United Nations. New York. 2020 (https://reliefweb.int/report/world/wfp-chief-warns-hunger-pandemic-covid-19-spreads-statement-un-security-council) Accessed April 27, 2020.

21. WHO. WHO and UNICEF warn of a decline in vaccinations during COVID-19. The World Health Organization. Geneva. 2020. (https://www.who.int/news/item/15-07-2020-who-and-unicef-warn-of-a-decline-in-vaccinations-during-covid-19). Accessed 19 February 2021

22. Oxfam. 12.000 people per day could die from COVID-19 linked hunger by end of year, potentially more than the disease, warns Oxfam. Oxfam International. 2020. (https://www.oxfam.org/en/press-releases/12000-people-day-could-die-covid-19-linked-hunger-end-year-potentially-more-disease). Accessed 19 February 2021.

23. WHO. COVAX: Working for global equitable access to COVID-19 vaccines. The World Health Organization. 2021. (https://www.who.int/initiatives/act-accelerator/covax). Accessed 22 February 2021

24. The Global Fund. The Global Fund Strategy 2017-2022 Investing to end epidemics. The Global Fund to Fight AIDS, Tuberculosis and Malaria. 2016. (https://www.theglobalfund.org/media/2531/core_globalfundstrategy2017-2022_strategy_en.pdf). Accessed 22 February 2021.

25. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, Fontanet A, Cauchemez S, Salje H (2020). Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590: 140-145

26. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, Online Edition. Rev. 1.

27. Murray CJL (1996). Rethinking DALYs. In: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Edited by: Murray CJL, Lopez AD. Boston: Harvard University Press.

28. GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396: 1204–1222.

29. IHME, 2021. Global Data Exchange – Global Results Tool. Institute of Health Metrics and Evaluation – University of Washington. (http://ghdx.healthdata.org/gbd-results-tool). Accessed 02 March 2021.

30. Murray JLC, Lopez AD. The Global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 : summary / edited by Christopher J. L. Murray, Alan D. Lopez. World Health Organization. Geneva.1996. (https://apps.who.int/iris/handle/10665/41864) Accessed 06 May 2020.

31. WHO. WHO methods and data sources for global burden of disease estimates 2000-2015, Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2018.4. World Health Organization. Geneva. 2018 (https://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf). Accessed. April 26, 2020.

32. World Population Review. Obesity Rates by Country 2021. World Population Review. 2021. (https://worldpopulationreview.com/country-rankings/obesity-rates-by-country). Accessed 23 February 2021.

33. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. *J Infect Public Health*. 2020. 13(10):1373-1380. doi: 10.1016/j.jiph.2020.06.021.

34. Tan CCS, Owen CJ, Tham CYL, Bertoletti A, van Dorp L, Balloux F. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. *bioRxiv* 2020.12.08.415703; doi: https://doi.org/10.1101/2020.12.08.415703

35. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*. 2020. 181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015.

36. Olayanju O, Bamidele O, Edem F, et al. SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers in Ibadan, Nigeria. *Am J Trop Med Hyg*. 2021 Jan;104(1):91-94. doi: 10.4269/ajtmh.20-1235.

37. Chibwana MG, Jere KC, Kamng'ona R, et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi [version 2; peer review: 2 approved]. *Wellcome Open Res*. 2020; 5: 199. (https://wellcomeopenresearch.org/articles/5-199). Accessed 26 February 2021.

38. Ojal J, Brand SPC, Were V et al. Revealing the extent of the COVID-19 pandemic in Kenya based on serological and PCR-test data *medRxiv* preprint doi: https://doi.org/10.1101/2020.09.02.20186817;

39. Sykes W, Mhlanga L, Swanevelder R, et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. 2021, Preprint (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-233375/v1]

40. Mulenga LB, Hines JZ, Fwoloshi S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. *Lancet Glob Health*. 2021 Mar 9:S2214-109X(21)00053-X. doi: 10.1016/S2214-109X(21)00053-X.

41. Sartorius B, Veerman LJ, Manyema M, Chola L, Hofman K. Determinants of Obesity and Associated Population Attributability, South Africa: Empirical Evidence from a National Panel Survey, 2008-2012. *PLoS One*. 2015;10(6):e0130218. doi: 10.1371/journal.pone.0130218.

42. Uganda MoH. Coronavirus (pandemic) COVID-19. Uganda Ministry of Health. (https://www.health.go.ug/covid/). Accessed 23 February 2021

43. Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University Corona Virus Resource Center. USA. (https://coronavirus.jhu.edu/map.html). Accessed 23 February 2021.

44. Cousins S. 2·5 million more child marriages due to COVID-19 pandemic. *Lancet.* 2020; 396(10257):1059. doi: 10.1016/S0140-6736(20)32112-7. PMID: 33038955; PMCID: PMC7544458.

45. Zuo J, A Dowell A, Pearce H, et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. *bioRxiv* 2020.11.01.362319; doi: https://doi.org/10.1101/2020.11.01.362319

46. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. *bioRxiv* 2020.11.15.383323; doi: https://doi.org/10.1101/2020.11.15.383323

Figures.

Figure 1. Comparison of baseline mortality and disease burdens (DALYs lost) predicted for the 12 months of 2020 for malaria, tuberculosis and HIV/AIDs (pre-lockdown impact), and up to 31 March 2021 for COVID-19, in sub-Saharan Africa. A1 & A2: Mortality and DALYs lost for sub-Saharan countries north of South Africa and Lesotho. B1 & B2: Mortality and DALYs lost for all sub-Saharan countries.

Figure 2. Mortality predicted for the 12 months of 2020 for malaria, tuberculosis and HIV/AIDs (pre-lockdown impact), and up to 31 March 2021 for COVID-19, in sub-Saharan Africa. A: Mortality for sub-Saharan countries north of South Africa and Lesotho. B: Mortality for all sub-Saharan countries.

SUPPLEMENTAL FILE

Relative burdens of COVID-19 and the malaria, tuberculosis and HIV/AIDS epidemics in sub-Saharan Africa in 2020. SUPPLEMENTARY FILE

David Bell[1*], Kristian Schultz Hansen[2]

[1]Independent Consultant, Issaquah, Washington, USA

[2]Department of Public Health and Centre for Health Economics and Policy, University of Copenhagen, Øster Farimagsgade 5A, 1014 Copenhagen K, Denmark.

*Corresponding author

David Bell, [1]25 Mt Quay Dr NW, Issaquah, WA 98027, USA, Email: bell00david@gmail.com, Ph: +1 206 953 8354

Supplementary information.

Table S1a. Estimated COVID-19 infections (individuals infected) and deaths by age in Sub-Saharan Africa excluding South Africa and Lesotho, up to 31 March 2021.

Age group	United Nations population estimate 2020[a]	Share of population infected (%)[b]	Infection fatality ratio (%)[c]	Estimated COVID-19 infections	Estimated COVID-19 deaths
0-4	164,804,603	2.282	0.003	3,761,278	113
5-9	147,530,309	2.282	0.001	3,367,033	34
10-14	130,237,158	2.282	0.001	2,972,357	30
15-19	112,354,975	2.282	0.003	2,564,238	77
20-24	95,039,505	2.282	0.006	2,169,053	130
25-29	79,611,837	2.282	0.013	1,816,953	236
30-34	66,961,607	2.282	0.024	1,528,241	367
35-39	55,972,752	2.282	0.040	1,277,447	511
40-44	45,533,164	2.282	0.075	1,039,187	779
45-49	36,505,391	2.282	0.121	833,150	1,008
50-54	28,697,760	2.282	0.207	654,959	1,356
55-59	22,713,657	2.282	0.323	518,386	1,674
60-64	17,441,001	2.282	0.456	398,050	1,815
65-69	12,682,251	2.282	1.075	289,443	3,112
70-74	8,585,543	2.282	1.674	195,945	3,280
75-79	5,010,511	2.282	3.203	114,353	3,663
80+	3,232,639	2.282	8.292	73,777	6,118
Total	1,032,914,663			23,573,850	24,302

[a] Reference (7).

[b] Assumed population share compatible with 13,031 COVID-19 deaths in total.

[c] Reference (25).

Table S1b. Estimated COVID-19 infections (individuals infected) and deaths by age in Sub-Saharan Africa, up to 31 March 2021.

Age group	United Nations population estimate 2020[a]	Share of population infected (%)[b]	Infection fatality ratio (%)[c]	Estimated COVID-19 Infections	Estimated COVID-19 deaths
0-4	170,823,061	6.541	0.003	11,173,573	335
5-9	153,576,204	6.541	0.001	10,045,452	100
10-14	135,944,992	6.541	0.001	8,892,191	89
15-19	117,485,136	6.541	0.003	7,684,728	231
20-24	100,167,519	6.541	0.006	6,551,979	393
25-29	85,020,504	6.541	0.013	5,561,209	723
30-34	72,510,463	6.541	0.024	4,742,925	1,138
35-39	60,906,502	6.541	0.040	3,983,907	1,594
40-44	49,462,677	6.541	0.075	3,235,364	2,427
45-49	39,829,404	6.541	0.121	2,605,250	3,152
50-54	31,464,591	6.541	0.207	2,058,106	4,260
55-59	24,999,129	6.541	0.323	1,635,198	5,282
60-64	19,290,886	6.541	0.456	1,261,821	5,754
65-69	14,093,620	6.541	1.075	921,867	9,910
70-74	9,510,448	6.541	1.674	622,080	10,414
75-79	5,609,970	6.541	3.203	366,949	11,753
80+	3,670,499	6.541	8.292	240,088	19,908
Total	1,094,365,605			71,582,686	77,463

[a] Reference (7).

[b] Assumed population share compatible with 41,551 COVID-19 deaths in total.

[c] Reference (25).



Figure 1. Comparison of baseline mortality and disease burdens (DALYs lost) predicted for the 12 months of 2020 for malaria, tuberculosis and HIV/AIDs (pre-lockdown impact), and up to 31 March 2021 for COVID-19, in sub-Saharan Africa. A1 & A2: Mortality and DALYs lost for sub-Saharan countries north of South Africa and Lesotho. B1 & B2: Mortality and DALYs lost for all sub-Saharan countries.



Figure 2. Mortality predicted for the 12 months of 2020 for malaria, tuberculosis and HIV/AIDs (pre-lockdown impact), and up to 31 March 2021 for COVID-19, in sub-Saharan Africa. A: Mortality for sub-Saharan countries north of South Africa and Lesotho. B: Mortality for all sub-Saharan countries.